Idera Pharmaceuticals Inc  

(Public, NASDAQ:IDRA)   Watch this stock  
Find more results for IDRA
2.77
-0.17 (-5.78%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.74 - 3.09
52 week 0.50 - 6.87
Open 2.92
Vol / Avg. 3.02M/4.43M
Mkt cap 228.14M
P/E     -
Div/yield     -
EPS -0.51
Shares 82.36M
Beta 2.20
Inst. own 30%
May 12, 2014
Q1 2014 Idera Pharmaceuticals, Inc. Earnings Release (Estimated) Add to calendar
Mar 13, 2014
Q4 2013 Idera Pharmaceuticals, Inc. Earnings Release
Mar 13, 2014
Q4 2013 Idera Pharmaceuticals, Inc. Earnings Conference Call - Webcast
Mar 5, 2014
Idera Pharmaceuticals, Inc. at Cowen Health Care Conference - Webcast
Feb 25, 2014
Idera Pharmaceuticals, Inc. at RBC Capital Markets Healthcare Conference - Webcast
Feb 11, 2014
Idera Pharmaceuticals, Inc. at Biotechnology Industry Organization CEO & Investor Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -152250.00% -38778.72%
Operating margin -151800.00% -38657.45%
EBITD margin - -38365.96%
Return on average assets -63.91% -76.44%
Return on average equity -107.39% -228.45%
Employees 18 -
CDP Score - -

Address

167 Sidney Street
CAMBRIDGE, MA 02139
United States - Map
+1-617-6795500 (Phone)
+1-617-6795592 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs). It is also evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. During the year ended December 31, 2011, the Company collaborated with Merck Sharp & Dohme Corp., for the use of agonists of TLRs 7, 8, and 9 as vaccine adjuvants for cancer, infectious diseases, and Alzheimer�s disease. In November 2011, the Company reacquired rights to IMO-2055 from Merck KGaA, Darmstadt, Germany, its former collaborator.

Officers and directors

James A. Geraghty Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Sudhir Agrawal President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Youssef El Zein Independent Vice Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Louis J. Arcudi III Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary
Age: 52
Bio & Compensation  - Reuters
Louis Brenner M.D. Senior Vice President, Chief Medical Officer
Age: 43
Bio & Compensation  - Reuters
Robert D. Arbeit M.D. Vice President - Clinical Development
Age: 65
Bio & Compensation  - Reuters
Timothy M. Sullivan Ph.D. Vice President - Development Programs and Alliance Management
Age: 58
Bio & Compensation  - Reuters
William S. Reardon CPA Lead Independent Director
Age: 66
Bio & Compensation  - Reuters
Julian C. Baker Director
Age: 48
Bio & Compensation  - Reuters
Mark A. Goldberg M.D. Director
Age: 54
Bio & Compensation  - Reuters